Merck Sharp & Dohme (MSD), the non-USA and Canada trading name for US pharma giant Merck & Co (NYSE: MRK), has entered into a second deal on epigenetics with Germany’s Proteros biostructures.
The new collaboration is aimed at developing small molecule compounds against an additional epigenetic target for the potential treatment of various cancers.
Under the terms of the deal, Proteros receives an upfront payment and research funding and will be eligible to receive development, regulatory and commercial milestone payments up to $167 million plus tiered royalties. Additional details of the collaboration were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze